Article
Endocrinology & Metabolism
Chen-Kai Chou, Shun-Yu Chi, Yi-Yung Hung, Yi-Chien Yang, Hung-Chun Fu, Jia-He Wang, Chueh-Chen Chen, Hong-Yo Kang
Summary: The study revealed that dysregulated expression of miR-146b and androgen receptor (AR) played critical roles in the tumorigenesis of papillary thyroid carcinoma (PTC). It was confirmed that miR-146b expression was significantly inversely correlated with AR expression. Further experiments showed that AR might bind to the androgen receptor element on the promoter region of miR-146b, leading to repression of miR-146b expression and reduction of PTC tumor aggressiveness. PTC patients with low AR/high miR-146b expression were associated with advanced tumor characteristics.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Oncology
Jinyuan Shi, Pu Wu, Lei Sheng, Wei Sun, Hao Zhang
Summary: This study identified a novel ferroptosis-related gene signature with 10 genes in PTC, which showed predictive value for patients' prognosis. High-risk and low-risk groups based on the signature had different survival rates, and the risk score was identified as an independent prognostic indicator. Functional roles of the differentially expressed genes were explored through GO enrichment and KEGG pathway analyses. Immune-related analysis showed significant differences in immune cell types and functions between high-risk and low-risk groups, and qRT-PCR confirmed expression differences of the genes in tumor tissue and normal thyroid tissue.
CANCER CELL INTERNATIONAL
(2021)
Article
Endocrinology & Metabolism
Francesca Galuppini, Simona Censi, Isabella Merante Boschin, Matteo Fassan, Marta Sbaraglia, Nicola Valeri, Jens Claus Hahne, Loris Bertazza, Giada Munari, Marco Galasso, Luciano Cascione, Susi Barollo, Massimo Rugge, Federica Vianello, Angelo Paolo Dei Tos, Caterina Mian, Gianmaria Pennelli
Summary: This study analyzed the miRNA expression profiles of different histological variants and mutations in papillary thyroid carcinoma (PTC) samples and found that miRNA signatures were associated with specific histotypes and BRAF mutations.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Medicine, General & Internal
Martina Mandarano, Marco Andolfi, Renato Colella, Massimo Monacelli, Andrea Polistena, Sonia Moretti, Guido Bellezza, Efisio Puxeddu, Alessandro Sanguinetti, Angelo Sidoni, Nicola Avenia, Francesco Puma, Jacopo Vannucci
Summary: This study found that high expressions of N-cadherin and AhR were associated with higher locoregional tumour aggressiveness, while PDTC/ATC more frequently showed high expression of CD147. Additionally, more aggressive neoplasms tended to have lower expression of E-cadherin. High levels of AhR were also found to be associated with recurrent/persistent diseases, particularly when combined with high N-cadherin expression.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Wojciech Gierlikowski, Katarzyna Broniarek, Lukasz Cheda, Zbigniew Rogulski, Marta Kotlarek-Lysakowska
Summary: In the context of papillary thyroid carcinoma, miR-181a-5p has been found to directly regulate the expression of SLC5A5, potentially reducing the efficacy of radioiodine treatment. This suggests that miR-181a-5p could serve as a promising target to enhance the efficacy of radioactive iodine therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Long Liu, Chao Jia, Gang Li, Qiusheng Shi, Lianfang Du, Rong Wu
Summary: A nomogram based on preoperative clinical and ultrasound indicators was constructed to predict the aggressiveness of solitary papillary thyroid carcinoma (PTC). Four predictors (age, tumor size, capsule abutment, and suspected cervical lymph nodes metastasis) showed good discrimination and calibration in both the primary and validation cohorts, indicating the nomogram's ability to predict PTC aggressiveness.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
Fan Yang, Yi-Li Zhou
Summary: This study identified a four-miRNA signature that can effectively predict the prognosis of PTC, helping in stratifying patients into high and low-risk groups. High-risk patients may benefit from more aggressive therapy and closer monitoring.
WORLD JOURNAL OF CLINICAL CASES
(2023)
Article
Endocrinology & Metabolism
Shuang Li, Ming-Yu Ran, Hong Qiao
Summary: The cell cycle plays a crucial role in the development and progression of papillary thyroid carcinoma (PTC), and long non-coding RNAs (lncRNAs) are important regulators of cell cycle processes. This study aimed to identify cell cycle-related lncRNAs (CCR-lncRNAs) that could predict the prognosis of PTC. Through analyses of RNA-seq and clinical data, a five-CCR-lncRNA signature was established and demonstrated to have reliable prognostic capability. Additionally, functional enrichment analyses showed that the signature was associated with cell cycle- and immune-related pathways. Overall, the newly developed risk signature based on CCR-lncRNAs could serve as a marker for predicting the progression-free interval in PTC.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Zedong Dai, Ran Wei, Hao Wang, Wenjuan Hu, Xilin Sun, Jie Zhu, Hong Li, Yaqiong Ge, Bin Song
Summary: The study demonstrates that a multimodality MRI-based radiomics model can accurately distinguish aggressiveness in PTC from non-aggressiveness PTC, providing valuable insights for treatment strategy and prognosis assessment in patients.
BMC MEDICAL IMAGING
(2022)
Article
Biochemical Research Methods
Wei Han, Dongchen Lu, Chonggao Wang, Mengdi Cui, Kai Lu
Summary: Key mRNAs, miRNAs, and mRNA-miRNA network involved in papillary thyroid carcinoma (PTC) have been identified through integrated analysis of gene and miRNA expression data, improving understanding of PTC pathogenesis.
CURRENT BIOINFORMATICS
(2021)
Article
Medicine, General & Internal
Mohammad Sheikh-Ahmad, Yara Shalata, Jacob Bejar, Hila Kreizman Shefer, Majd F. F. Sirhan, Monica Laniado, Ibrahim Matter, Abed Agbarya, Maria Reut, Ekaterina Yovanovich, Leonard Saiegh
Summary: This study evaluated the correlation between different immunohistochemical markers and the risk of extrathyroidal extension and metastases in papillary thyroid carcinoma (PTC). The results showed that the staining levels of Metallothionein, E-Cadherin and MCM2 significantly distinguished between benign thyroid tumors and PTC. The intensity of E-Cadherin staining was significantly lower in PTC with metastases.
MEDICINA-LITHUANIA
(2023)
Article
Biochemistry & Molecular Biology
Yu Guan, Bijun Wang, Tao Zhang, Sifan Gao, Zichuan Cao, Meng Zhang, Chaozhao Liang
Summary: A microRNA predicting signature was established to assess the prognosis of PRCC patients, demonstrating good discrimination and efficiency. The signatures were identified as independent risk factors with better prognostic capacity than other classifiers, and showed better predictive performance than clinicopathologic features.
DNA AND CELL BIOLOGY
(2021)
Article
Medical Laboratory Technology
Lei Dai, Weidong Zhang, Xianjiang Wu, Shuihong Zhou
Summary: Overall, miR-203a-3p inhibits the oncogenic characteristics of TPC-1 and KTC-1 cells via suppressing MAP3K1 and activating autophagy. Our findings might enrich the understanding and the therapeutic strategies of PTC.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2022)
Article
Oncology
Rujia Qin, Chunyan Li, Xuemin Wang, Zhaoming Zhong, Chuanzheng Sun
Summary: By analyzing the expression profiles of IRGs and TFs in PTC patients, an IRG model that can predict PFI was constructed, and a key IRG related to prognosis was identified. Experimental results showed that this key IRG is closely related to immune activity.
CANCER CELL INTERNATIONAL
(2021)
Article
Health Care Sciences & Services
Kecheng Jiang, Bei Lin, Yu Zhang, Kaining Lu, Fan Wu, Dingcun Luo
Summary: A risk score model based on four pyroptosis-related genes (CASP6, CASP9, IL-18, and NOD1) was established to predict the recurrence risk of papillary thyroid carcinoma (PTC). The model divided the samples into high- and low-risk clusters, showing significant differences in disease-free survival (DFS). A nomogram combining clinical factors was also developed, and the relationships with immune characteristics and tumor gene mutations were analyzed.
JOURNAL OF PERSONALIZED MEDICINE
(2023)